Madoni, SN, Costa, PB, Coburn, JW, and Galpin, AJ. Effects of foam rolling on range of motion, peak torque, muscle activation, and the hamstrings-to-quadriceps strength ratios. J Strength Cond Res 32(7): 1821-1830, 2018-To examine the effects of foam rolling (FR) on range of motion (ROM), peak torque (PT), hamstrings-to-quadriceps (H:Q) ratios, and muscle activation. Twenty-two recreationally active women (mean age ± SD = 21.55 ± 1.82 years, 161.91 ± 6.58 cm, 61.47 ± 10.54 kg) volunteered for this study. Participants performed pre- and posttests analyzing PT and surface electromyography (EMG) of their dominant limb, completing maximal knee extension and flexion at 3 different velocities. Participants foam rolled the hamstrings muscles or sat for the control condition between the pre- and posttests. Hamstrings ROM increased in the FR condition from (mean ± SE) 123.23 ± 3.49 to 126.41 ± 3.62° (p < 0.001) and decreased in the control condition from 118.82 ± 4.25 to 117.95 ± 4.29° (p = 0.013). Concentric hamstrings PT and conventional H:Q ratios decreased after both conditions, with smaller decreases after FR (p ≤ 0.05). No significant changes were found for eccentric hamstrings PT, eccentric hamstrings EMG, or functional H:Q ratios (p > 0.05). Foam rolling resulted in greater changes in hamstrings ROM without creating a deficit in PT or muscle activation when compared with the control group. When compared with other methods of stretching, FR may be beneficial in increasing ROM without decreasing functional H:Q ratios.
ResearchEffect of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: a randomized, placebo controlled, cross-over study AbstractBackground: The purpose of the present investigation was to determine the effects of EPA/DHA supplementation on resting and exercise-induced inflammation and oxidative stress in exercisetrained men. Fourteen men supplemented with 2224 mg EPA+2208 mg DHA and a placebo for 6 weeks in a random order, double blind cross-over design (with an 8 week washout) prior to performing a 60 minute treadmill climb using a weighted pack. Blood was collected pre and post exercise and analyzed for a variety of oxidative stress and inflammatory biomarkers. Blood lactate, muscle soreness, and creatine kinase activity were also measured.
We examined whole body aerobic capacity and myocellular markers of oxidative metabolism in lifelong endurance athletes [n = 9, 81 ± 1 yr, 68 ± 3 kg, body mass index (BMI) = 23 ± 1 kg/m(2)] and age-matched, healthy, untrained men (n = 6; 82 ± 1 y, 77 ± 5 kg, BMI = 26 ± 1 kg/m(2)). The endurance athletes were cross-country skiers, including a former Olympic champion and several national/regional champions, with a history of aerobic exercise and participation in endurance events throughout their lives. Each subject performed a maximal cycle test to assess aerobic capacity (VO(2max)). Subjects had a resting vastus lateralis muscle biopsy to assess oxidative enzymes (citrate synthase and βHAD) and molecular (mRNA) targets associated with mitochondrial biogenesis [peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) and mitochondrial transcription factor A (Tfam)]. The octogenarian athletes had a higher (P < 0.05) absolute (2.6 ± 0.1 vs. 1.6 ± 0.1 l/min) and relative (38 ± 1 vs. 21 ± 1 ml·kg(-1)·min(-1)) VO(2max), ventilation (79 ± 3 vs. 64 ± 7 l/min), heart rate (160 ± 5 vs. 146 ± 8 beats per minute), and final workload (182 ± 4 vs. 131 ± 14 W). Skeletal muscle oxidative enzymes were 54% (citrate synthase) and 42% (βHAD) higher (P < 0.05) in the octogenarian athletes. Likewise, basal PGC-1α and Tfam mRNA were 135% and 80% greater (P < 0.05) in the octogenarian athletes. To our knowledge, the VO(2max) of the lifelong endurance athletes is the highest recorded in humans >80 yr of age and comparable to nonendurance trained men 40 years younger. The superior cardiovascular and skeletal muscle health profile of the octogenarian athletes provides a large functional reserve above the aerobic frailty threshold and is associated with lower risk for disability and mortality.
The deadlift exercise is commonly performed to develop strength and power, and to train the lower-body and erector spinae muscle groups. However, little is known about the acute training effects of a hexagonal barbell vs. a straight barbell when performing deadlifts. Therefore, the purpose of this study was to examine the hexagonal barbell in comparison with the straight barbell by analyzing electromyography (EMG) from the vastus lateralis, biceps femoris, and erector spinae, as well as peak force, peak power, and peak velocity using a force plate. Twenty men with deadlifting experience volunteered to participate in the study. All participants completed a 1 repetition maximum (1RM) test with each barbell on 2 separate occasions. Three repetitions at 65 and 85% 1RM were performed with each barbell on a third visit. The results revealed that there was no significant difference for 1RM values between the straight and hexagonal barbells (mean ± SD in kg = 181.4 ± 27.3 vs. 181.1 ± 27.6, respectively) (p > 0.05). Significantly greater normalized EMG values were found from the vastus lateralis for both the concentric (1.199 ± 0.22) and eccentric (0.879 ± 0.31) phases of the hexagonal-barbell deadlift than those of the straight-barbell deadlift (0.968 ± 0.22 and 0.559 ± 1.26), whereas the straight-barbell deadlift led to significantly greater EMG values from the bicep femoris during the concentric phase (0.835 ± 0.19) and the erector spinae (0.753 ± 0.28) during the eccentric phase than the corresponding values for the hexagonal-barbell deadlift (0.723 ± 0.20 and 0.614 ± 0.21) (p ≤ 0.05). In addition, the hexagonal-barbell deadlift demonstrated significantly greater peak force (2,553.20 ± 371.52 N), peak power (1,871.15 ± 451.61 W), and peak velocity (0.805 ± 0.165) values than those of the straight-barbell deadlift (2,509.90 ± 364.95 N, 1,639.70 ± 361.94 W, and 0.725 ± 0.138 m·s, respectively) (p ≤ 0.05). These results suggest that the barbells led to different patterns of muscle activation and that the hexagonal barbell may be more effective at developing maximal force, power, and velocity.
The purpose of this study was to examine the effects of a 3-wk taper on the physiology of competitive distance runners. We studied seven collegiate distance runners (20+/-1 yr, 66+/-1 kg) before and after a 3-wk taper. The primary measures included 8-km cross-country race performance, gastrocnemius single muscle fiber size and function (peak force, shortening velocity, and power), baseline and exercise-induced gene expression 4 h after a standardized 8-km run, citrate synthase activity, and maximal and submaximal cardiovascular physiology (oxygen consumption, ventilation, heart rate, and respiratory exchange ratio). Race performance improved by 3% following taper (P<0.05). Myosin heavy chain (MHC) IIa fiber diameter (+7%, P<0.05), peak force (+11%, P=0.06), and absolute power (+9%, P<0.05) increased following taper. In addition to the MHC IIa adaptations, taper elicited a distinct postexercise gene response. Specifically, the induction of MuRF-1 was attenuated following taper, whereas MRF4, HSP 72, and MT-2A displayed an exaggerated response (P<0.05). No changes were observed in MHC I size or function, baseline gene expression, citrate synthase activity, or cardiovascular function. Our findings show that tapered training in competitive runners promoted MHC IIa fiber remodeling and an altered transcriptional response following the same exercise perturbation, with no adverse affects on aerobic fitness. Together, these results provide a myocellular basis for distance runners to taper in preparation for peak performance.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.